Sulfanilamide

From Wikipedia, the free encyclopedia
(Redirected from Prontalbin)

Template:Short description Template:DMCA Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Sulfanilamide
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
AHFS/Drugs.comsalonemide Consumer Drug Information
ATC codePage Template:Plainlist/styles.css has no content.
Identifiers
  • 4-aminobenzenesulfonamide
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC6H8N2O2S
Molar mass172.20 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
Density1.08 g/cm3
Melting point165 °C (329 °F)
  • O=S(=O)(c1ccc(N)cc1)N
  • InChI=1S/C6H8N2O2S/c7-5-1-3-6(4-2-5)11(8,9)10/h1-4H,7H2,(H2,8,9,10) checkY
  • Key:FDDDEECHVMSUSB-UHFFFAOYSA-N checkY
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content.  (verify)

Sulfanilamide (also spelled sulphanilamide) is a sulfonamide antibacterial drug. Chemically, it is an organic compound consisting of an aniline derivatized with a sulfonamide group.[1] Powdered sulfanilamide was used by the Allies in World War II to reduce infection rates and contributed to a dramatic reduction in mortality rates compared to previous wars.[2][3] Sulfanilamide is rarely if ever used systemically due to toxicity and because more effective sulfonamides are available for this purpose. Modern antibiotics have supplanted sulfanilamide on the battlefield; however, sulfanilamide remains in use today in the form of topical preparations, primarily for treatment of vaginal yeast infections such as vulvovaginitis caused by Candida albicans.[4][5][6][7]

The term "sulfanilamides" is also sometimes used to describe a family of molecules containing these functional groups. Examples include:

Mechanism of action

As a sulfonamide antibiotic, sulfanilamide functions by competitively inhibiting (that is, by acting as a substrate analogue of) enzymatic reactions involving para-aminobenzoic acid (PABA).[8][9] Specifically, it competitively inhibits the enzyme dihydropteroate synthase.[5][10] PABA is needed in enzymatic reactions that produce folic acid, which acts as a coenzyme in the synthesis of purines and pyrimidines. Mammals do not synthesize their own folic acid so are unaffected by PABA inhibitors, which selectively kill bacteria.[11]

However, this effect can be reversed by adding the end products of one-carbon transfer reactions, such as thymidine, purines, methionine, and serine. PABA can also reverse the effects of sulfonamides.[5][12][11]

History

Sulfanilamide was first prepared in 1908 by the Austrian chemist Paul Josef Jakob Gelmo (1879–1961)[13][14] as part of his dissertation for a doctoral degree from the Technische Hochschule of Vienna.[15] It was patented in 1909.[16]

Gerhard Domagk, who directed the testing of the prodrug Prontosil in 1935,[17] and Jacques Tréfouël and Thérèse Tréfouël, who along with Federico Nitti and Daniel Bovet in the laboratory of Ernest Fourneau at the Pasteur Institute, determined sulfanilamide as the active form,[18] are generally credited with the discovery of sulfanilamide as a chemotherapeutic agent. Domagk was awarded the Nobel Prize for his work.[19]

In 1937, Elixir sulfanilamide, a medicine consisting of sulfanilamide dissolved in diethylene glycol, poisoned and killed more than one hundred people as a result of acute kidney failure, prompting new US regulations for drug testing. In 1938, the Food, Drug and Cosmetic Act was passed. It was only the solvent and not the sulfanilamide that was the problem, as sulfanilamide was widely and safely used at the time in both tablet and powder form.[20]

Chemical and physical properties

Laboratory synthesized sulfanilamide

Sulfanilamide is a yellowish-white or white crystal or fine powder. It has a density of 1.08 g/cm3 and a melting point of 164.5-166.5 °C. The pH of a 0.5% aqueous solution of Sulfanilamide is 5.8 to 6.1. It has a λmax of 255 and 312 nm.[5]

Solubility: One gram of sulphanilamide dissolves in approximately 37 ml alcohol or in 5 ml acetone. It is practically insoluble in chloroform, ether, or benzene.[5]

Contraindications

Sulfanilamide is contraindicated in those known to be hypersensitive to sulfonamides, in nursing mothers, during pregnancy near term, and in infants less than two months of age.[5]

Adverse effects

Since sulfanilamide is used almost exclusively in topical vaginal preparations these days, adverse effects are typically limited to hypersensitivity or local skin reactions. If absorbed, systemic side effects commonly seen with sulfanilamides may occur.[5]

Pharmacokinetics

A small amount of sulfanilamide is absorbed following topical application or when administered as a vaginal cream or suppository (through the vaginal mucosa). It is metabolized by acetylation like other sulfonamides and excreted through the urine.[5]

References

Page Template:Reflist/styles.css has no content.

  1. ^ Script error: No such module "Template wrapper".
  2. ^ Page Module:Citation/CS1/styles.css has no content.Steinert D (2000). "The Use of Sulfanilamide in World War II". The History of WWII Medicine. Archived from the original on 7 June 2016.
  3. ^ Page Module:Citation/CS1/styles.css has no content."Class 9 Items: Drugs, Chemicals and Biological Stains Sulfa Drugs". Library of Congress Web Archives. Archived from the original on 4 December 2013. Retrieved 13 June 2014.
  4. ^ Page Module:Citation/CS1/styles.css has no content."Sulfanilamide". PubChem. National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine.
  5. ^ a b c d e f g h Page Module:Citation/CS1/styles.css has no content.Scholar E (1 January 2007). "Sulfanilamide". In Enna SJ, Bylund DB (eds.). xPharm: The Comprehensive Pharmacology Reference. New York: Elsevier. pp. 1–5. doi:10.1016/b978-008055232-3.62694-7. ISBN 978-0-08-055232-3. Retrieved 2 October 2021.
  6. ^ Page Module:Citation/CS1/styles.css has no content."US FDA Label: AVC (sulfanilamide) Vaginal Cream 15%" (PDF). United States Food & Drug Administration. Archived from the original (PDF) on 16 February 2017. Retrieved 3 October 2021.
  7. ^ Page Module:Citation/CS1/styles.css has no content."Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 30 January 2017. Retrieved 2 October 2021.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Castelli LA, Nguyen NP, Macreadie IG (May 2001). "Sulfa drug screening in yeast: fifteen sulfa drugs compete with p-aminobenzoate in Saccharomyces cerevisiae". FEMS Microbiology Letters. 199 (2): 181–4. doi:10.1111/j.1574-6968.2001.tb10671.x. PMID 11377864.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Kent M (2000). Advanced Biology. Oxford University Press. p. 46. ISBN 978-0-19-914195-1.
  10. ^ Page Module:Citation/CS1/styles.css has no content.Sharma S (January 1997). "Chapter 18 - Antifolates". In Sharma S, Anand N (eds.). Pharmacochemistry Library. Approaches to Design and Synthesis of Antiparasitic Drugs. Vol. 25. Elsevier. pp. 439–454. doi:10.1016/s0165-7208(97)80040-2. ISBN 9780444894762.
  11. ^ a b Page Module:Citation/CS1/styles.css has no content.Brunton LL, Hilal-Dandan R, Knollmann BC (2018). Goodman & Gilman's the pharmacological basis of therapeutics (13th ed.). New York: McGraw Hill Education. ISBN 978-1-259-58473-2. OCLC 993810322.
  12. ^ Page Module:Citation/CS1/styles.css has no content.Wormser GP, Chambers HF (1 February 2001). "The Antimicrobial Drugs, Second Edition by Eric Scholar and William Pratt New York: Oxford University Press, 2000. 607 pp., illustrated. $98.50 (cloth); $69.50 (paper)". Clinical Infectious Diseases. 32 (3): 521. doi:10.1086/318515. ISSN 1058-4838.
  13. ^ Page Module:Citation/CS1/styles.css has no content.Gelmo P (1908). "Über Sulfamide der p-Amidobenzolsulfonsäure". Journal für Praktische Chemie. 77 (1): 369–382. doi:10.1002/prac.19080770129. ISSN 1521-3897.
  14. ^ Page Module:Citation/CS1/styles.css has no content."Paul Gelmo". Encyclopedia.com.
  15. ^ Page Module:Citation/CS1/styles.css has no content.Gelmo P (14 May 1908). "Über Sulfamide der p-Amidobenzolsulfonsäure". Journal für Praktische Chemie. 77: 369–382. doi:10.1002/prac.19080770129.
  16. ^ On 18 May 1909, Deutsches Reich Patentschrift number 226,239 for sulfanilamide was awarded to Heinrich Hörlein of the Bayer corporation.
  17. ^ Page Module:Citation/CS1/styles.css has no content.Domagk G (15 February 1935). "Ein Beitrag zur Chemotherapie der bakteriellen Infektionen". Deutsche Medizinische Wochenschrift. 61 (7): 250. doi:10.1055/s-0028-1129486. S2CID 70515565.
  18. ^ Page Module:Citation/CS1/styles.css has no content.Tréfouël J, Tréfouël T, Nitti F, Bovet D (23 November 1935). "Activité du p-aminophénylsulfamide sur l'infection streptococcique expérimentale de la souris et du lapin". C. R. Soc. Biol. 120: 756.
  19. ^ Page Module:Citation/CS1/styles.css has no content.Bovet D (1988). "Les étapes de la découverte de la sulfamidochrysoïdine dans les laboratoires de recherche de la firme Bayer à Wuppertal-Elberfeld (1927–1932)". Une chimie qui guérit : Histoire de la découverte des sulfamides. Médecine et Société (in français). Paris: Payot. p. 307.
  20. ^ Page Module:Citation/CS1/styles.css has no content.Ballentine C. "Sulfanilamide Disaster" (PDF). fda.gov. FDA. Archived from the original (PDF) on 14 February 2020. Retrieved 5 May 2022.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found. Lua error in mw.title.lua at line 404: bad argument #2 to 'title.new' (unrecognized namespace name 'Portal'). Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.

Retrieved from "https://cosmopedia.co/index.php?title=Sulfanilamide&oldid=2420686"